Patients with metastatic castrate-resistant prostate cancer (mCRPC) who were treated with enzalutamide (Xtandi) were more likely to experience central nervous system (CNS) events or fatigue than patients treated with the combination of abiraterone acetate (Zytiga) and prednisone.
The immunotherapy agent atezolizumab (Tecentriq) reduced the size of tumors by 24% in patients with metastatic urothelial carcinoma (mUC), according to phase II clinical trial results presented at the 2016 ASCO Annual Meeting.
Combination therapy nivolumab (Opdivo) and ipilimumab (Yervoy) resulted in reduced disease progression risk of 58% when compared with ipilimumab alone in patients with advanced melanoma. Additionally, nivolumab monotherapy showed greater risk reduction (45%) compared with ipilimumab single-agent treatment.
Howard L. (Jack) West, MD, medical oncologist, director, Thoracic Oncology Program, Swedish Cancer Institute, discusses emerging agents on the horizon for patients with T790M-mutant patients with non-small cell lung cancer.
Combining PD-L1 inhibitor atezolizumab with investigational OX40 agonist MOXR0916 treatment showed early signs of antitumor activity in solid tumor types and was well tolerated by patients.
Combination therapy dabrafenib and trametinib showed positive outcomes in patients with BRAF V600E-mutant NSCLC, according to phase II trial data presented at the 2016 ASCO Annual Meeting.
Men with nmCRPC demonstrated a median time to PSA progression of 28.7 months and a median time to radiographic progression of 41.4 months, according to updated safety and efficacy data involving abiraterone acetate and low-dose prednisone.
Updated findings from the phase III CheckMate-057 and -017 trials showed sustained improvements in overall survival (OS) data of nivolumab (Opdivo) treatment in pretreated patients with nonsquamous or squamous non-small cell lung cancer (NSCLC).
A preliminary safety and efficacy trial of a device using tumor treating fields (TTF) administered to unresectable pancreatic cancer patients found that the treatment was tolerable and safe when combined with gemcitabine.
Treatment with the delta-like protein 3 (DLL3)-targeted antibody-drug conjugate rovalpituzumab tesirine demonstrated single-agent activity and a manageable safety profile for patients with recurrent/refractory SCLC.
Pooled analysis, presented at the 2016 ASCO Annual Meeting, showed the safety profile of dabrafenib and trametinib is consistent with reports from three individual studies.
A faculty of experts presented a compelling discussion on the state of the art for EGFR-targeted TKIs during the 2016 ASCO Annual Meeting.
The number of brain metastases does not have an impact on overall survival (OS) in patients with non-small cell lung cancer (NSCLC) with an EGFR mutation or ALK rearrangement, Cleveland Clinic investigators discovered.
Treatment with dabrafenib (Tafinlar) plus trametinib (Mekinist) resulted in a complete response in 9 of 19 patients with stage IIIb/c BRAF V600 melanoma, according to results from a phase II trial presented at the 2016 ASCO Annual Meeting.
A joint analysis of the "ABC" trials comparing anthracycline versus non-anthracycline treatment in patients with high-risk, HER2-negative breast cancer has failed to demonstrate non-inferiority of the non-anthracycline regimen.
Three years after the pembrolizumab (Keytruda) clinical trial for advanced melanoma that led to the drug's FDA approval, 40% of the patients are still alive.
Clinical trials studying a biomarker-based treatment showed substantially better results than non-personalized treatment methods in a meta-analysis that examined 13,203 patients from phase I trials.
Patients with pancreatic cancer who were treated at high-volume centers had a 16-month improvement in median overall survival (OS) versus those who received treatment at community medical centers.
A bevy of clinical trials exploring the use of nab-paclitaxel (Abraxane) in various combinations and treatment settings aim to uncover future strategies for treating patients with pancreatic adenocarcinoma, which remains one of the deadliest forms of cancer.
"This combination seems to be well-tolerated by patients with manageable toxicity, and overall efficacy for the small group seems to be favorable."
Manish Shah, MD, Bartlett Family Associate Professor of Medicine, director, Gastrointestinal Oncology Program, Weill Cornell Medical College, discusses doing more than just surgery for patients with locally advanced stomach cancer.
Kenneth Wang, MD, director of the Advanced Endoscopy Group and Esophageal Neoplasia Clinic, Mayo Clinic, discusses his opposition for Barrett's esophagus screening as a preventative measure for esophageal adenocarcinoma.
<div style="color:#003668"><em>"When there is a mismatch between the human genetics and bacterial genetics, this may be one of the factors that leads to gastrointestinal cancer."<p align="right"><span style="color:#747474">- Keith Wilson, MD</span></em></div></p>
Second-line treatment of metastatic pancreatic cancer proved to be feasible and beneficial, particularly for patients who received nab-paclitaxel in addition to gemcitabine, according to extension data from a phase III trial.
Patients with pancreatic adenocarcinoma enrolled on clinical trials have "profoundly improved survival" compared with patients in the general population, suggesting that oncologists who use trial data to prognosticate may be missing the mark, according to researchers whose work was presented at the 2016 Gastrointestinal Cancers Symposium.
Mismatch repair-deficient gastrointestinal (GI) tumors are highly responsive to checkpoint blockade with anti
Using genomic and proteomic characterization of pancreatic cancer tumors, researchers from Vall d
The latest results from an open-label, phase Ib study of the STAT3 inhibitor BBI-608 (napabucasin) with a standard chemotherapy (FOLFIRI with or without bevacizumab) in the treatment of advanced colorectal cancer, have been presented at the ASCO 2016 Gastrointestinal Symposium. Evidence of antitumor activity and a favorable safety profile were seen in phase I studies.
Avelumab, an investigational anti-PD-L1 antibody, showed clinical activity as both a second-line and maintenance therapy in patients, with unresectable gastric or gastroesophageal junction (GEJ) cancer, according to data from a phase Ib presented at the 2016 Gastrointestinal Cancers Symposium.
An orally administered first-in-class cancer stemness inhibitor, BBI608, administered twice daily with weekly paclitaxel has promising activity in patients with refractory, heavily pretreated metastatic pancreatic cancer; particularly in patients who are taxane naive.